A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
NCI-2022-10845 (AHOD2131)
NCT05675410
 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
CHUL ET CENTRE MERE-ENFANT SOLEIL
|
Hodgkin's Disease |
Dr. Bruno Michon
Valerie-Eve Julien
418-525-4444
|
A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
HD11
NCT05180097
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Hodgkin's Disease |
Dr. Stéphanie Corriveau-Désilets
Christine Lawson
819-346-1110 poste 12942
|
A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
HD11
NCT05180097
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Hodgkin's Disease |
Dr. Kelly Davison
Judit Kokai
438-888-1582
|
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
SGN35-015
NCT01716806
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Hodgkin's Disease |
Dr. Kelly Davison
|
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
SGN35-015
NCT01716806
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Hodgkin's Disease |
Dr. Nathalie Johnson
Alessandra Figueiredo De Vasconcelos
514-340-8222 poste 26823
|
A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
KEYFORM-008 (MK-4280A-008)
NCT05508867
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Hodgkin's Disease |
Dr. Nathalie Johnson
Chadi Zakaria
514-340-8222 poste 28326
Emma Starr
514-340-8222 poste 28443
|
A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
KEYFORM-008 (MK-4280A-008)
NCT05508867
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Hodgkin's Disease |
Dr. Kelly Davison
Claude Vertzagias
514-934-1934 poste 34909
|
Groupe d'étude en oncologie du Québec